Law ❯Securities Law ❯Class Action Lawsuit
False and Misleading Statements Litigation Risks Investor Damages Lead Plaintiff Contingency Fee Basis
Investors have until December 8 to join the lawsuit, following significant losses due to questions over the efficacy of Kenvue's product, phenylephrine.
